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Background: Obesity, type 2 diabetes mellitus (T2D) and unhealthy blood lipid profile are strongly associated with
the risk of developing cardiovascular disease (CVD). We examined whether blood lipid changes with short term
administration of the weight lowering drug, sibutramine and lifestyle modification in obese and overweight high-
risk patients was associated with T2D status at screening.
Methods: The Sibutramine Cardiovascular OUTcomes (SCOUT) trial included obese and overweight patients at
increased risk of cardiovascular events. All patients received guidance on diet and exercise plus once-daily 10 mg
sibutramine during the 6-week, single blind lead-in period. Multivariable regression models were used to
investigate factors associated with changes in lipid levels during the first four weeks of treatment.
Results: A total of 10 742 patients received at least one dose of sibutramine during the 6-week lead-in period of
SCOUT. After four weeks, patients experienced mean reductions in low density lipoprotein (LDL-C) 0.19 mmol/L,
high density lipoprotein (HDL-C) 0.019 mmol/L, very low density lipoprotein (VLDL-C) 0.08 mmol/L, total cholesterol
(TC) 0.31 mmol/L and triglycerides 0.24 mmol/L (p < 0.0001 for each). Four week changes in LDL-C, HDL-C and
total cholesterol for patients without vs. with T2D were: LDL-C:-0.25 mmol/L vs. -0.18 mmol/L, P = 0.0004; HDL-C:
-0.03 mmol/L vs. -0.02 mmol/L, P = 0.0014; total cholesterol: -0.37 mmol/l vs. -0.29 mmol/l, P = 0.0009. Multivariable
regression analysis showed that similar decreases in body mass index (BMI) affected lipid changes differently
according to diabetes status. A 1 kg/m
2 decrease in BMI in patients with T2D was associated with -0.09 mmol/L in
LDL-C (P < 0.0001) and -0.01 mmol/L in HDL-C (P = 0.0001) but larger changes of -0.16 mmol/L LDL-C and -0.03
mmol/L in HDL-C (P < 0.0001 for both) in patients without T2D.
Conclusion: Short term weight management with sibutramine therapy in obese or overweight high-risk patients
induced significant mean reductions for all lipids. Those without T2D benefited most. Patients with hyperlipidaemia
and the less obese patients also had greater falls in LDL-C and TC during weight loss. The trial is registered at
ClinicalTrial.gov number: NCT00234832.
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Obesity, hyperlipidaemia and type-2 diabetes mellitus
(T2D) are well known risk factors for developing cardio-
vascular disease (CVD)[1,2]. It has been shown that a
reduction in low-density lipoprotein cholesterol (LDL-C)
reduces cardiovascular risk[3,4]. Reducing body mass
index (BMI) in obese patients also reduces several risk
factors associated to the development of CVD[2]. How-
ever, obese patients seldom manage to achieve and
maintain weight loss through dietary changes and exer-
cise alone[5]. The effects of weight loss and glycaemic
control of T2D in terms of incidence of macrovascular
disease are less clear[6]. To date no study has assessed
the benefits of long term weight loss in high-risk
patients. The Sibutramine Cardiovascular OUTcomes
(SCOUT) trial included 10 742 obese or overweight
high-risk patients where all patients received 10 mg
sibutramine hydrochloride monohydrate (sibutramine)
once daily for six weeks during the single-blind, lead-in
phase of the study. This lead-in phase provides an
opportunity to assess lipid changes during short term
treatment with sibutramine and compare the responses
in patients with and without T2D. This comparison pro-
vides preliminary data and highlights some of the vari-
ables to be considered in the ongoing randomized phase
of the SCOUT trial.
Methods
SCOUT is an ongoing, randomized, double-blind, pla-
cebo controlled, multicenter clinical study to assess the
efficacy of sibutramine in reducing cardiovascular out-
come in obese or overweight high-risk patients. During
the 6-week, single-blind, lead-in period, all patients were
treated with sibutramine 10 mg daily together with
advice on diet and exercise (a 600 kcal/day deficit diet
plan and an exercise program comprising >150 min of
moderate exercise per week). Data presented in this
paper are from the first four weeks of the 6-week
SCOUT lead-in period before patients were randomized
into the double-blind phase of the study.
Individuals eligible for inclusion in the study were
men and women aged 55 years or older, with a BMI ≥
27 kg/m
2 and ≥ 45 kg/m
2 or a BMI ≥ 25 kg/m
2 and
<27 kg/m
2 with a waist circumference ≥ 102 cm (men)
or ≥ 88 cm (women). Patients enrolled under the initial
inclusion criteria were required to have diagnosed T2D
together with at least one defined risk factor (hyperten-
sion, dyslipidaemia, current smoker, or diabetic nephro-
pathy), or a history of coronary vascular disease (CVD),
defined as coronary artery disease, peripheral arterial
occlusive disease or stroke. A full description of the
inclusion and exclusion criteria has been published pre-
viously[7]. Due to a lower than expected overall primary
outcome rate, enrollment criteria were adjusted to
amplify the recruitment of the highest risk patients 15
months after the first patient was enrolled. In particular,
patients enrolled under the later restricted enrollment
criteria were required to have both a history of CVD
and a history of T2D with at least one additional risk
factor.
Patients had a physical examination performed at the
initial screening visit where information on body weight,
vital signs, blood chemistry and haematology were
obtained. Patients had follow-up visits every two weeks
after the initial screening visit until the baseline visit,
which was the start of the double-blind randomization
period of the study. Patients who required an increase
in their anti-hypertensive medication during this period
were not to be randomized into the trial. At every fol-
low-up visit, information on body weight and vital signs
were obtained. Data on blood chemistry (fasting) and
haematology were obtained at the screening visit and
after four weeks of treatment. Some of the patients had
a second haematology or a blood chemistry sample
taken in relation to the screening visit or the visit after
four weeks of treatment. For the present analysis, we
used only the second blood samples if no data on the
first sample were available. High density lipoprotein
(HDL-C), low density lipoprotein (LDL-C), very low
density lipoprotein (VLDL-C), total cholesterol (TC) and
triglycerides were measured in mmol/L. HDL-C, VLDL-
C, TC and triglycerides were measured directly in the
blood samples in a certified central laboratory. LDL-C
was estimated by Friedwald’s equation when triglyceride
levels were <4.52 mmol/L (calculated LDL-C cholesterol =
[TC] - [HDL-C-cholesterol] - [triglycerides/5]), but
was measured directly if triglyceride levels exceeded
>4.52 mmol/L.
The trial is registered at ClinicalTrial.gov number:
NCT00234832.
Ethics
All participating patients gave informed written consent
prior to participation. All approvals were obtained from
relevant ethical committees and the study was per-
formed in compliance with the Declaration of Helsinki.
Statistics
Continuous variables were evaluated using both para-
metric (paired and two-sample t-tests) and non-para-
metric (Wilcoxon signed-rank and Wilcoxon rank sum
tests) methods, with the latter providing similar results
unless otherwise specified. Multivariable regression ana-
lysis was performed in order to identify factors asso-
ciated with changes in lipid levels. Demographic and
patient characteristics collected at the screening visit
and listed in Table 1 were included as covariates in our
analyses. When a significant two-way interaction was
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included in our final model were those with known or
potential effects on the lipids of interest.
All calculations were made using SAS®, version 9.1
(SAS Institute, Cary, North Carolina) on preliminary
data available by September 2006. P-values ≤ 0.05 were
regarded as statistically significant.
Results
Included in the lead-in period of the SCOUT trial were
10 742 patients who took at least one dose of sibutra-
mine. Patients with an unknown risk category were
excluded (n = 13) as done previously[7]. Mean age and
BMI for the study population were 63.8 years (Standard
error of the mean (SEM) = 0.06) and 34.4 kg/m
2 (SEM
= 0.04) respectively. Overall, patients experienced mean
reductions in low density lipoprotein (LDL-C) (0.19
mmol/L), high density lipoprotein (HDL-C) (0.019
mmol/L), very low density lipoprotein (VLDL-C) (0.08
mmol/L), total cholesterol (TC) (0.31 mmol/L) and tri-
glycerides (0.24 mmol/L) (P < 0.0001). Screening charac-
teristics stratified according to diabetes status are
presented in Table 1. The T2D group (n = 8981) com-
prised 83.7% of the overall study population. Of these
30.4% (n = 2734) were on treatment with insulin.
Screening values
Mean LDL-C, HDL-C and TC at screening were found to
be significantly greater in patients without T2D when
compared to patients with T2D (Table 1) (P value for dif-
ference < 0.0001). However, mean VLDL-C and triglycer-
ides at screening were significantly greater in patients
with T2D than in patients without T2D (Table 1) (P for
difference < 0.0001). Patients with T2D had a higher BMI
than patients without T2D at screening (34.6 kg/m
2 vs.
33.4 kg/m
2, P < 0.0001) (Table 1).
Overall 84.2% (n = 9033) of the patients had the meta-
bolic syndrome according to the Adult Treatment Panel
III defined criteria[8]. The majority (87.5%, n = 7901) of
the patients with T2D met the criteria whereas patients
without T2D usually did not (12.5%, n = 1132; p for dif-
ference < 0.0001).
Changes in lipids and BMI
During the 4-week investigational period, all lipids were
significantly decreased from screening values both in
patients with and without T2D (P < 0.0001) (Table 2).
Patients without T2D had greater decreases in LDL-C
(P = 0.0004), HDL-C (P = 0.0014) and TC (P = 0.0009)
levels than patients with T2D (Table 2).
Table 1 Descriptive characteristics of enrolled patients
NON-T2D T2D
N 1748 (16.3%) 8981 (83.7%)
Age (years) 63.8 [0.14] 63.8 [0.07]
Male gender (%) 1148 (65.7%) 5063 (56.4%)
Screening data and medication:
Weight (kg) 95.0 [0.35] 96.3 [0.16]
Waist Circumference men (cm) 112.5 [0.30] 114.8 [0.15]
Waist Circumference women (cm) 104.3 [0.46] 110.0 [0.18]
Hip Circumference men (cm) 110.8 [0.28] 112.6 [0.14]
Hip Circumference women (cm) 116.7 [0.45] 119.1 [0.19]
Body Mass Index (kg/m
2) 33.4 [0.10] 34.6 [0.05]
Systolic Blood Presurre (mmHg) 136.3 [0.31] 138.6 [0.13]
Diastolic Blood Pressure (mmHg) 78.4 [0.20] 77.6 [0.09]
Pulse rate (b.p.m.) 68.0 [0.23] 71.7 [0.11]
LDL-C (mmol/L) 3.00 [0.02] 2.81 [0.01]
HDL-C (mmol/L) 1.25 [0.007] 1.18 [0.003]
VLDL-C (mmol/L) 0.86 [0.008] 0.95 [0.004]
TC (mmol/L) 5.13 [0.03] 5.01 [0.01]





Smoking at screening 10.3% 9.6%
Drinking at screening 63.4% 53.5%
Patient history of:
Stroke 9.2% 8.3%
Peripheral artery disease (PAD) 8.2% 11.4%
Coronary artery disease (CAD) 91.5% 60.8%
Acute Myocardial Infarction (AMI) 58.8% 37.1%
Congestive heart failure (CHF) 9.2% 8.4%
Hyperlipidemia 76.2% 81.8%
Hypertension 73.2% 90.7%
Presented are means with standard error of the mean within [ ].
13 patients with unknown risk category were excluded.
N denotes number of patients.
Dichotomous values are presented as percentages.
ACEi denotes angiotensin converting enzyme inhibitor.
Smoking at screening is defined as current tobacco use.
Drinking at screening is defined as at least 3 drinks per year. Table 2 Changes in lipid variables over four weeks in






LDL-C (mmol/L) -0.25 [-0.29, -0.21] -0.18 [-0.20, -0.17] 0.0004
HDL-C (mmol/L) -0.03 [-0.04, -0.02] -0.02 [-0.02, -0.01] 0.0014
VLDL-C (mmol/L) -0.09 [-0.11, -0.08] -0.08 [-0.09, -0.07] 0.1564
TC (mmol/L) -0.37 [-0.41, -0.33] -0.29 [-0.31, -0.28] 0.0009
Triglycerides (mmol/L) -0.22 [-0.27, -0.18] -0.25 [-0.27, -0.22] 0.3231
BMI (kg/m
2) -0.81 [-0.84, -0.78] -0.73 [-0.75, -0.72] 0.3887
In all instances, within-group changes from baseline were statistically
significant (P < 0.0001)
Data presented as means and 95% Confidence intervals.
*P-values for difference in mean changes.
13 patients with unknown risk category were excluded.
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together with dietary advice and exercise, mean BMI
was reduced by 0.75 kg/m
2 in patients who had mea-
surements at both time points. Further, we found
patients without T2D had greater mean decreases in
BMI than patients with T2D (0.81 kg/m
2 vs. 0.74 kg/m
2,
P < 0.0001). Figures 1 and 2 depict the relationship
between the magnitude of BMI reduction (quartiles) fol-
lowing four weeks of treatment and the corresponding
reductions in lipids, with reductions in BMI producing
greater lipid level reductions overall.
Results from multivariable regression models including
all covariates from Table 1 are listed in the Additional
File 1. Notably, we found that a reduction in BMI of 1
kg/m
2 affected the change in LDL-C, HDL-C and TC
differently depending on the patient’sd i a b e t e ss t a t u s
(LDL-C: P for interaction 0.0086; HDL-C: P for interac-
tion 0.0018; TC: P for interaction 0.0055). Therefore, we
stratified the change in BMI according to patient dia-
betes status (Figures 1, 2 and 3). BMI reductions
appeared to influence triglyceride and VLDL-C similarly
in patients with and without T2D (Fig 3; triglycerides: P
for interaction 0.6251; VLDL-C: P for interaction
0.8734). No interaction was found for T2D with gender
or age (data not shown).
Presented in Figure 3 are the effects of a positive T2D
status and the effects of a decrement in BMI (1 kg/m
2)
stratified according to T2D status on predicted changes
in lipids from the multivariable regression models. The
effect of a BMI decrement (1 kg/m
2) in patients without
Figure 1 Mean lipid changes in patients with T2D according to BMI reduction quartiles. Lipid changes in patients with T2D stratified
according to BMI reduction quartile (1-4). Quartile 1 represents the least reduction in BMI whereas quartile 4 represents the greatest. Mean lipid
values are listed for each quartile with 95% confidence intervals. All values are measured in mmol/L. 13 patients with unknown risk category
were excluded.
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TC levels than a similar BMI decrement in patients with
T2D (Figure 3). Also illustrated in Figure 3 are the
effects of T2D status on lipid changes. A positive T2D
status predicted greater mean reductions in LDL-C (0.11
mmol/l, P < 0.0001), HDL-C (0.014 mmol/l, P = 0.031),
and TC (0.10 mmol/l, P = 0.0032), but lesser mean
reductions in VLDL-C (0.03 mmol/l, P = 0.0007) and
triglycerides (0.8 mmol/l, P = 0.0110), when all other
factors are accounted for (Figure 3).
Other results
In our multivariable regression analyses with informa-
tion on screening levels for examined lipids, we found
male gender to be significantly associated with reduc-
tions in all examined lipids (LDL-C 0.69 mmol/L; HDL-
C 0.02 mmol/L; VLDL-C 0.05 mmol/L; TC 0.13 mmol/
L and triglycerides 0.09 mmol/L) (Additional File 1). A
history of smoking was associated with lesser mean
reductions in VLDL-C, TC and triglycerides (Additional
File 1). The use of statins was found to help induce
Figure 2 Mean lipid changes in patients without T2D according to BMI reduction quartiles. Lipid changes in patients without T2D
stratified according to BMI reduction quartile (1-4). Quartile 1 represents the least reduction in BMI whereas quartile 4 represents the greatest.
Mean lipid values are listed with 95% confidence intervals. All values are measured in mmol/L. 13 patients with unknown risk category were
excluded.
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and TC (0.31 mmol/L), but was not significantly asso-
ciated with selective effects on HDL-C and triglycerides.
Furthermore, the use of fibrates showed significantly
higher values for VLDL-C (0.02 mmol/L) and triglycer-
ides (0.08 mmol/L) once the other covariates had been
accounted for (Additional Fi l e1 ) .N oi n t e r a c t i o nw a s
found with respect to the change in VLDL-C, (P for
interaction 0.9044) or triglycerides, (P for interaction
0.9095) when both the use of fibrates and the degree of
weight loss was considered.
Discussion
Obese and overweight high-risk patients with and with-
out T2D experienced mean reductions in LDL-C, HDL-
C, VLDL-C, TC and triglycerides following four weeks
of weight loss therapy with sibutramine and lifestyle
changes (Table 2). Patients without T2D showed the
greatest mean reductions in LDL-C, HDL-C and TC
(Table 2). We found that T2D status had a significant
influence on all lipids following four weeks of sibutra-
mine treatment during the 6-week lead-in period of the
study (Figure 3). Furthermore, T2D status also induced
different effects on LDL-C, HDL-C and TC levels for
each 1 kg/m
2 decrement in BMI (Figure 3).
Overall, average LDL-C levels decreased by 7.3% in
patients with and without T2D during the treatment
period. There is a strong causal link between elevated
levels of LDL-C and the development of atherosclerotic
vascular disease [9-13]. Obese, overweight high-risk and
abdominally obese patients are often susceptible to
develop an adverse lipid profile also known as the ‘lipid
triad’ (elevated LDL-C, low HDL-C, elevated triglycer-
ides) [14] which is one of several contributing risk fac-
t o r sf o rd e v e l o p i n gC V D .T h u s ,i ti se v i d e n tt h a t
lowering LDL-C levels is an important step in combat-
ing their increased risk of CVD[15]. We saw a greater
mean LDL-C reduction in patients without T2D than in
patients with T2D. These findings are to some extent
related to the higher LDL-C screening values observed
in patients without T2D than in patients with T2D (3.0
mmol/L vs. 2.8 mmol/L respectively, P < 0.0001). Also,
this can relate to the well known fact that individuals
prone to develop cardiovascular disease have higher TC
and LDL-C levels and, for a standard reduction in satu-
rated fat intake, their responsiveness to a standardized
dietary change is greater[16]. Further, patients without
T2D experienced greater reductions in BMI than
patients with T2D, thus amplifying the observed
decreases in TC and LDL-C (Figure 1 and 2). This smal-
ler weight loss in patients with T2D has been well docu-
mented but the reasons for the differences in response
remain obscure[17]. The use of statins was associated
with greater reductions in LDL-C in both patients with
and without T2D (Additional File 1) which implies an
interactive effect of stains with dietary changes and sibu-
tramine treatment. However, the use of statins was sig-
nificantly greater among patients without T2D than
Figure 3 The effects of T2D and 1 kg/m
2 BMI-decrement in patients with/without T2D on predicted lipid changes. Multivariable
regression analysis demonstrating the effects of a 1 kg/m
2 BMI decrement in patients with/without T2D and the effect of T2D on predicted lipid
changes. The model is adjusted for all covariates in Table 1. 13 patients with unknown risk category were excluded.
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which could contribute to the greater mean LDL-C
reduction found in patients without T2D. These three
features namely the greater fall in BMI, the use of sta-
tins and the greater hyperlipidaemia, therefore, seemed
to have combined to induce the greater fall in TC and
LDL-C in the patients without T2D.
HDL-C, often labeled as being a ‘good cholesterol’
because of its protective effects against the development
of CHD [18,19], is known to decrease during an acute,
non-steady state phase of weight loss, but then increases
above baseline levels following long term weight loss
maintenance[20]. In this SCOUT trial overall HDL-C
levels fell by 1.4% on average as a result of four weeks
of weight management with sibutramine, dietary advice
and exercise. No increase in HDL-C levels following
four weeks of sibutramine therapy has been reported
previously[21]. The Sibutramine Trial of Obesity Reduc-
tion and Maintenance (STORM) was, however, a
longer-term two year study which assessed the effect of
sibutramine as a pharmacological adjunct to dietary
advice and exercise. Sibutramine was found to induce
significant increases in HDL-C levels following six
months of therapy[22,23] but no acute changes during
the initial period of weight loss. The study also sug-
gested that the HDL-C increases were greater than
expected for weight loss alone, and identified sibutra-
mine as an inducer of HDL-C independent of the effects
of weight changes[23]. Thus, our results on HDL-C are
concordant with previously described short term
responses where an initial decrease in HDL-C is
expected. The long term results will be available after
SCOUT ends in 2009.
According to our multivariable regression models, the
effects of a BMI decrement (1 kg/m
2) in patients with
T2D predicts a 0.01 mmol/l greater reduction in trigly-
ceride levels than equivalent BMI reductions in patients
without T2D (Figure 3) whereas the VLDL-C changes
were similar (Figure 3). These changes may reflect the
impact of changes in dietary composition and/or nutri-
ent intake as well as an effect of sibutramine-amplified
weight loss in improving insulin sensitivity in the insu-
lin-resistant T2D patients. However, the changes are
dominated by factors other than the presence of T2D
because the actual 4-week mean changes show no sig-
nificant difference in decreases for triglyceride and
VLDL-C in patients with and without T2D (Table 2).
According to our multivariable regression analyses, the
use of fibrates was associated with higher levels of trigly-
ceride and VLDL-C levels (Additional File 1). However,
the clinical decision to use fibrates may reflect a greater
CVD problem in these patients and therefore confounds
the interpretation of the changes observed. Our findings
on triglyceride reductions are similar to the previously
reported findings with sibutramine in the STORM study
[23], but the reduced relative and absolute risk for CVD
following reductions in triglyceride levels is not as great
as the benefit of lower LDL-C levels[24].
A high HDL-C/LDL-C ratio is predictive of a reduced
incidence of CVD. The mean HDL-C/LDL-C ratio at
screening was 0.46 for patients without T2D and 0.48
for patients with T2D. HDL-C/LDL-C ratios were seen
in both patients with (0.51) and without T2D (0.49) fol-
lowing four weeks of treatment with sibutramine and
lifestyle changes. Thus, despite the expected initial
reductions in HDL-C, the overall increases in the HDL-
C/LDL-C ratios were favorable and reflect the greater
decreases in LDL-C levels.
The multivariable regression analyses showed that
patients with T2D did reduce their LDL-C and HDL-C
levels with weight loss. Nevertheless these patients with
T2D had marked dyslipidaemia which was one of the
risk requirements in the recruitment of the T2D
patients for this trial. The relatively early adjustment of
patient selection also amplified the proportion of T2D
patients who already had cardiovascular events. Thus it
is not surprising that dyslipidaemia rates were high and
that there was a fall in LDL-C levels with weight loss
following dietary adjustment and exercise with sibutra-
mine as a pharmacological adjunct. The dietary advice
with diet sheets specified a marked reduction in satu-
rated fatty acid intake and an increase in dietary n-3
fatty acids. The data do emphasize the value of taking a
proactive approach to weight reduction in patients with
T2D despite their resistance to weight loss and the com-
monly held approach that one should concentrate on
the co-morbidities of obesity in T2D management rather
than tackling the weight loss per se.
Limitations to this study
The data presented in this paper are from the lead-in
period of the SCOUT trial covering four weeks of sibu-
tramine treatment with all patients receiving sibutra-
mine 10 mg daily as a test to their possible sensitivity to
the drug. Therefore we cannot make conclusions relat-
ing to any specific effects of sibutramine treatment and
lipid changes. Further, there were no dose changes
either to allow any dose response analyses. Thus, we are
unable to distinguish the effect induced by sibutramine
alone from the effects caused by dietary advice and
exercise.
Patients were requested to fast for every visit that
included blood samples and we have specific statements
from the patients that they complied. However, patient
visits were carried out at different times during the day;
for example, if the first visit was in the morning and the
second in the late afternoon, this could potentially influ-
ence measured lipid levels. Thus, the lipid profile may
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Regression towards the mean is a problem we have
tried to overcome by including our initial lipid screening
values as explanatory variables for all analyses. Further,
potential two-way interactions (i.e., stratification-by-
baseline factor) were evaluated in an attempt to evaluate
changes in the dependent variable for potential regres-
sion towards the mean (data not shown).
Notably, the SCOUT trial was not specifically
designed to compare lipid changes following four weeks
of treatment with sibutramine as an adjunct to dietary
advice and exercise which is a limitation.
LDL-C levels were either measured directly or indir-
ectly (by calculation). If triglyceride levels exceeded
>4.52 mmol/L then LDL-C levels were measured
directly. The use, which is common practice, of an esti-
mated LDL-C gives some uncertainty compared to
direct measurement.
Conclusions
Our study shows that short-term sibutramine therapy
with dietary advice and exercise in obese or overweight
high risk patients with and without T2D is associated
with overall improvements in lipid profiles. LDL-C levels
decreased significantly in patients with and without
T2D. Patients without T2D experienced greater
decreases in LDL-C and TC for each 1 kg/m
2decrement
in BMI than patients with T2D. HDL-C levels
decreased, but these findings may be attributed to the
acute effects of weight loss during the short duration of
the study. Hyperlipidaemia at screening also predicted
greater benefit from the weight loss measures but
whether the changes in BMI and lipids translate into a
clinical benefit will be further clarified when the
SCOUT trial ends. Our preliminary results are consis-
tent with the use of sibutramine treatment with dietary
advice and exercise to improve the treatment of obesity
and overweight patients regardless of diabetes status.
Further studies are required to confirm these findings in
this patient population.
Additional file 1: Estimated effect of variables from Table 1on lipid
changes according to multivariable regression analyses. The
additional file contains the results from the multivariable regression
analysis examining the effects on lipid changes when controlling for all
variables listed in Table 1
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